Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21707226 | 1.00 | BTK (0.83) | BTKEGFR | |
| SCHEMBL28536320 | 1.00 | BTK (0.83) | BTKEGFR | |
| SCHEMBL29948723 | 1.00 | BTK (0.83) | BTKEGFR | |
| SCHEMBL29948662 | 1.00 | BTK (0.83) | BTKEGFR | |
| SCHEMBL21706936 | 0.91 | BTK (1.00) | BTKEGFR | |
| SCHEMBL21707234 | 0.91 | BTK (1.00) | BTKEGFR | |
| SCHEMBL21707075 | 0.89 | BTK (1.00) | BTKEGFR | |
| SCHEMBL21707229 | 0.89 | BTK (0.85) | BTKEGFR | |
| SCHEMBL21707237 | 0.88 | BTK (1.00) | BTKEGFR | |
| SCHEMBL22222727 | 0.88 | BTK (1.00) | BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116096369-A | Polymorphs of bruton's tyrosine kinase inhibitor, and preparation method and application thereof | 上海海雁医药科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116096369-A | Polymorphs of bruton's tyrosine kinase inhibitor, and preparation method and application thereof | 上海海雁医药科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-112334469-B | BTK inhibitor and pharmaceutically acceptable salt and polymorph thereof and application thereof | 上海海雁医药科技有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-112334469-B | BTK inhibitor and pharmaceutically acceptable salt and polymorph thereof and application thereof | 上海海雁医药科技有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20210395247-A1 | BTK INHIBITORS, PHARMACEUTICALLY ACCEPTABLE SALTS, POLYMORPHS AND APPLICATION THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| US-20210395247-A1 | BTK INHIBITORS, PHARMACEUTICALLY ACCEPTABLE SALTS, POLYMORPHS AND APPLICATION THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| EP-3851438-A1 | BTK INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT, POLYMORPH AND APPLICATION THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd (CN) | 2021-07-21 | — | — | EP | disclosed |
| CN-112334469-A | BTK inhibitor and pharmaceutically acceptable salt and polymorph thereof and application thereof | 上海海雁医药科技有限公司 | 2021-02-05 | — | — | CN | disclosed |
| CN-112334469-A | BTK inhibitor and pharmaceutically acceptable salt and polymorph thereof and application thereof | 上海海雁医药科技有限公司 | 2021-02-05 | — | — | CN | disclosed |
| WO-2020187267-A1 | BTK INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT, POLYMORPH AND APPLICATION THEREOF | 上海海雁医药科技有限公司 | 2020-09-24 | — | — | WO | disclosed |
| WO-2020187267-A1 | BTK INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT, POLYMORPH AND APPLICATION THEREOF | 上海海雁医药科技有限公司 | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395247-A1 | BTK INHIBITORS, PHARMACEUTICALLY ACCEPTABLE SALTS, POLYMORPHS AND APPLICATION THEREOF | BTK, SYK, LYN | BTK 1/4885EGFR 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.